FDA declines to approve Enzyvant regenerative therapy on manufacturing concerns
The company was hoping to win its first approval for the therapy, RVT-802, aimed at treating congenital athymia, a disorder…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.